Two Medical Companies Form Partnership To Treat Type 2 Diabetes
Better Therapeutics and Glooko Join Forces to Revolutionize Type 2 Diabetes Treatment in the U.S.
Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.
In a bid to revolutionize the treatment of Type 2 diabetes in the United States, digital therapeutics company Better Therapeutics (BTTX) has announced a strategic partnership with Glooko, a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions.
This partnership aims to speed up the adoption of AspyreRx, a novel prescription digital therapeutic developed by Better Therapeutics, designed to improve glycemic control in adults living with Type 2 diabetes.
AspyreRx is a cognitive behavioral therapy-based application that provides personalized treatment plans to help patients make lifestyle modifications which can ultimately lead to better control of their blood glucose levels.
The integration of this innovative solution into Glooko's platform is expected to enhance remote patient monitoring capabilities, and provide healthcare providers with valuable insights into patient behaviors and health outcomes. This, in turn, will enable more informed and timely clinical decision making.
Better Therapeutics and Glooko: A Powerful Collaboration
Better Therapeutics, based in San Francisco, California, is a pioneer in the development of prescription digital therapeutics to treat cardiometabolic diseases. The company's mission aligns perfectly with Glooko's, which is to transform diabetes care by making it more connected and data-driven.
A New Era in Diabetes Care
The partnership between Better Therapeutics and Glooko signifies a new era in diabetes care. By leveraging digital technology and data analytics, these companies are poised to transform the treatment landscape for Type 2 diabetes in the U.S.
As we move towards a future where healthcare is increasingly personalized and data-driven, such collaborations will play a crucial role in improving patient outcomes and reducing healthcare costs. As a reader, this partnership could potentially impact you or someone you know dealing with type 2 diabetes by providing more efficient, personalized care.
As an investor it's important to stay updated with major news. Get real-time stock market alerts and research by creating an account here.
Sources: